Question · asked by 1 review

Peginterferon alpha‐2a vs peginterferon alpha‐2b: Liver morbidity

It is very uncertain whether peginterferon alpha‐2a changes liver‐related morbidity Number of events compared with peginterferon alpha‐2b (very low certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
Peginterferon alpha‐2a vs peginterferon alpha‐2b
Liver‐related morbidity Number of events · patients with chronic hepatitis C.
It is very uncertain whether peginterferon alpha‐2a changes liver‐related morbidity Number of events compared with peginterferon alpha‐2b (very low certainty).
Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C (2014) · Cochrane Headline outcomes only
RR 3 [0.7, 12.93]1 study · 36 participantsVery low

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C
2014 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.